GlassScriptPhysician profile
Dewey Howell
NPI 1467808279
$1,729.24
in general payments reported to CMS, 2019-2025
23 companies · $771 in 2025
The $771 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.12 · 2022: $262 · 2023: $263 · 2024: $380 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $413.09 | 2021-2025 | |
| Novo Nordisk INC | $221.93 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $169.29 | 2022-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $125.20 | 2023-2025 | Airsupra, Farxiga |
| Insmed, INC. | $87.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.02 | 2024-2025 | Jardiance |
| Pfizer INC. | $76.49 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.82 | 2024-2025 | Caplyta |
| Inspire Medical Systems, INC. | $67.13 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $54.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $53.98 | 2023-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $46.17 | 2022-2023 | |
| Corcept Therapeutics | $40.88 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $40.02 | 2025 | Nexletol |
| Amgen INC. | $37.42 | 2025 | Otezla, Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $24.41 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $20.40 | 2023 | |
| Glaxosmithkline, LLC. | $19.61 | 2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $18.62 | 2023 | Cologuard Collection Kit |
| Ardelyx, INC. | $18.41 | 2025 | Ibsrela |
| Ascensia Diabetes Care US INC. | $13.16 | 2023 | |
| Phathom Pharmaceuticals, INC. | $12.90 | 2025 | Voquezna |
| Genentech USA, INC. | $10.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewey Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.